Influenza vaccine, anti-influenza drugs, and rapid diagnosis in Japan.
The percentage of individuals receiving influenza vaccine is markedly lower in Japan than in many other economically advanced countries. To increase the rate of coverage, the current practice of giving people two inoculations instead of one needs to be changed. In addition, free vaccination services for the elderly and high-risk patients need to be offered. Amantadine is available for the treatment of influenza type A infection in Japan. Moreover, zanamivir, a neuraminidase inhibitor effective against both influenza type A and B viruses, has been approved in Japan. A rapid diagnosis kit for influenza type A virus is available in Japan. With the current threat of new pandemic influenza viruses emerging, it is necessary to actively confront influenza in Japan by increasing the vaccine coverage rate, by employing amantadine and neuraminidase inhibitors for influenza virus infection, and by providing rapid diagnosis of influenza.
Sugaya
N
N
Department of Pediatrics, Nippon Kokan Hospital, 1-2-1 Kokandori, Kawasaki-ku, Kawasaki, Kanagawa 210-0852, Japan. sugaya-n@za2.so-net.ne.jp
D000547:Amantadine / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006146:Guanidines; D006801:Humans; D007252:Influenza Vaccines / Q000627:therapeutic use*; D007251:Influenza, Human / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy; D008297:Male; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D011714:Pyrans; D011933:Reagent Kits, Diagnostic / Q000592:standards*; D012794:Sialic Acids / Q000627:therapeutic use; D014611:Vaccination; D053243:Zanamivir
D000998:Antiviral Agents; D006146:Guanidines; D007252:Influenza Vaccines; D011714:Pyrans; D011933:Reagent Kits, Diagnostic; D012794:Sialic Acids; D000547:Amantadine; D009439:Neuraminidase; D053243:Zanamivir